MEDICAGO ANNOUNCES COLLABORATION WITH ACAMBIS TO EVALUATE VACCINE PRODUCTION USING PROFICIA(TM)

Medicago, Inc. announced today the signature of an agreement with Acambis Inc., the US subsidiary of Acambis plc (LSE: ACM; NASDAQ: ACAM), to evaluate the expression of recombinant vaccines using Medicago's plant-based Proficia(TM) system. Medicago will receive milestone payments from Acambis to assess the feasibility of using Medicago's Proficia(TM) Protein Technology for the production of vaccines. Medicago expects to announce further agreements in the area of vaccine development and manufacturing.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/September2005/27/c4303.html)